Moderna is developing a 2-in-1 vaccine against Covid and influenza. His stock is skipping.

Text size

Moderna plans to announce the development of a vaccine candidate that will protect against Covid-19 and influenza, which will be known as mRNA-1073. The company will also announce a pediatric vaccine called mRNA-1365, which combines its experimental vaccine against respiratory syncytial virus with its experimental vaccine against human metapneumovirus.

The news came less than an hour before the company began an investor event to discuss the company’s clinical development pipeline. Top Moderna executives (ticker: MRNA), including CEO Stéphane Bancel, new chief medical officer Dr Paul Burton and company president Dr Stephen Hoge, were due to appear.

Modern

shares were up 5.9% on Thursday after starting its virtual R&D day, which is expected to start at 8 a.m. ET. The stock fell 3.1% on Wednesday but is up 304.8% this year.

In a press release, Moderna said it plans to announce a number of pipeline updates during the R&D Day presentation.

“Today, we are announcing the first step of our new respiratory vaccine program with the development of a single dose vaccine that combines a COVID-19 booster and an influenza booster,” Bancel said in a statement. “We are making progress in recruiting patients into our rare disease programs and are fully enrolled in our personalized cancer vaccine trial. We believe this is just the start of a new era of information-based drugs.

The company also said it will discuss new data from a Phase 1 study of its respiratory syncytial virus vaccine. The company said interim data from the study showed that a single vaccination with the vaccine, known as mRNA-1345, increased the titers of neutralizing antibodies against the RSV-A virus by 14-fold. and 10 times against RSV-B virus. The company tested three different dose levels, but said there was no significant difference in the antibody response between the dose levels.

The company said it plans to begin a Phase 2/3 study of the RSV vaccine by the end of this year.

Moderna was a very different company on its last day of virtual R&D in September 2020. Still a clinical stage company at the time, Moderna had no products authorized or approved. That changed months later when the United States Food and Drug Administration cleared Moderna’s Covid-19 vaccine, which is expected to generate $ 20.1 billion in revenue this year alone.

At the time, Moderna set up a development pipeline that included its Covid-19 vaccine, personalized cancer vaccines and other products, including a range of prophylactic vaccine programs.

He also announced for the first time that day that he planned to develop an influenza vaccine.

Write to [email protected]